Enhancing Intranasal Delivery and Bioavailability of Dihydroergotamine Utilizing Chitosan Nanoparticles

Table 2

Area under the curve (AUC) and absolute bioavailability (%) of DHE formulations in rats (n = 3).

Route	Dose (mg/kg)	AUC0min − ∞ (ng·min·kg/mL/mg); Mean	Absolute bioavailability (%); Mean ± STDV
Intravenous DHE solution	0.4	13299.9 ± 973.8	100
Intranasal DHE solution	0.4	7066.7 ± 1088.3	53.2 ± 7.7
Intranasal DHE chitosan nanoparticles	0.4	10905 ± 1153.9	82.5 ± 12.3